Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents
Targeting neovessels in chronic tendinopathies has emerged as a new therapeutic approach and several embolization agents have been reported. The aim of this study was to investigate the feasibility of embolization with different agents in a porcine model of patellar tendinopathy and evaluate their s...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/9/1530 |
| _version_ | 1797486001755521024 |
|---|---|
| author | Julien Ghelfi Ian Soulairol Olivier Stephanov Marylène Bacle Hélène de Forges Noelia Sanchez-Ballester Gilbert Ferretti Jean-Paul Beregi Julien Frandon |
| author_facet | Julien Ghelfi Ian Soulairol Olivier Stephanov Marylène Bacle Hélène de Forges Noelia Sanchez-Ballester Gilbert Ferretti Jean-Paul Beregi Julien Frandon |
| author_sort | Julien Ghelfi |
| collection | DOAJ |
| description | Targeting neovessels in chronic tendinopathies has emerged as a new therapeutic approach and several embolization agents have been reported. The aim of this study was to investigate the feasibility of embolization with different agents in a porcine model of patellar tendinopathy and evaluate their safety and efficacy. Eight 3-month-old male piglets underwent percutaneous injection of collagenase type I to induce patellar tendinopathies (<i>n</i> = 16 tendons). They were divided into four groups (2 piglets, 4 tendons/group): the control group, 50–100 µm microspheres group, 100–300 µm microspheres group, and the Imipenem/Cilastatin (IMP/CS) group. Angiography and embolization were performed for each patellar tendon on day 7 (D7). The neovessels were evaluated visually with an angiography on day 14. The pathological analysis assessed the efficacy (Bonar score, number of neovessels/mm<sup>2</sup>) and safety (off-target persistent cutaneous ischemic modifications and presence of off-target embolization agents). The technical success was 92%, with a failed embolization for one tendon due to an arterial dissection. Neoangiogenesis was significantly less important in the embolized groups compared to the control group angiographies (<i>p</i> = 0.04) but not with respect to histology (Bonar score <i>p</i> = 0.15, neovessels <i>p</i> = 0.07). Off-target cutaneous embolization was more frequently depicted in the histology of the 50–100 µm microspheres group (<i>p</i> = 0.02). Embolization of this animal model with induced patellar tendinopathy was technically feasible with different agents and allowed assessing the safety and efficacy of neovessel destruction. Particles smaller than 100 µm seemed to be associated with more complications. |
| first_indexed | 2024-03-09T23:27:54Z |
| format | Article |
| id | doaj.art-053d5b4c507f427580c053ee27e4ea6a |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T23:27:54Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-053d5b4c507f427580c053ee27e4ea6a2023-11-23T17:14:42ZengMDPI AGJournal of Personalized Medicine2075-44262022-09-01129153010.3390/jpm12091530Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization AgentsJulien Ghelfi0Ian Soulairol1Olivier Stephanov2Marylène Bacle3Hélène de Forges4Noelia Sanchez-Ballester5Gilbert Ferretti6Jean-Paul Beregi7Julien Frandon8Faculty of Medicine, University of Grenoble Alpes, 38000 Grenoble, FranceDepartment of Pharmacy, Nîmes University Hospital, 30900 Nîmes, FranceAnatomopathology Department, Grenoble University Hospital, 38000 Grenoble, FranceFaculty of Medicine, Montpellier Nîmes University, RAM-PTNIM, 30900 Nîmes, FranceDepartment of Medical Imaging, Nîmes University Hospital, Imagine UR UM 103, University of Montpellier, 34090 Montpellier, FranceDepartment of Pharmacy, Nîmes University Hospital, 30900 Nîmes, FranceFaculty of Medicine, University of Grenoble Alpes, 38000 Grenoble, FranceDepartment of Medical Imaging, Nîmes University Hospital, Imagine UR UM 103, University of Montpellier, 34090 Montpellier, FranceDepartment of Medical Imaging, Nîmes University Hospital, Imagine UR UM 103, University of Montpellier, 34090 Montpellier, FranceTargeting neovessels in chronic tendinopathies has emerged as a new therapeutic approach and several embolization agents have been reported. The aim of this study was to investigate the feasibility of embolization with different agents in a porcine model of patellar tendinopathy and evaluate their safety and efficacy. Eight 3-month-old male piglets underwent percutaneous injection of collagenase type I to induce patellar tendinopathies (<i>n</i> = 16 tendons). They were divided into four groups (2 piglets, 4 tendons/group): the control group, 50–100 µm microspheres group, 100–300 µm microspheres group, and the Imipenem/Cilastatin (IMP/CS) group. Angiography and embolization were performed for each patellar tendon on day 7 (D7). The neovessels were evaluated visually with an angiography on day 14. The pathological analysis assessed the efficacy (Bonar score, number of neovessels/mm<sup>2</sup>) and safety (off-target persistent cutaneous ischemic modifications and presence of off-target embolization agents). The technical success was 92%, with a failed embolization for one tendon due to an arterial dissection. Neoangiogenesis was significantly less important in the embolized groups compared to the control group angiographies (<i>p</i> = 0.04) but not with respect to histology (Bonar score <i>p</i> = 0.15, neovessels <i>p</i> = 0.07). Off-target cutaneous embolization was more frequently depicted in the histology of the 50–100 µm microspheres group (<i>p</i> = 0.02). Embolization of this animal model with induced patellar tendinopathy was technically feasible with different agents and allowed assessing the safety and efficacy of neovessel destruction. Particles smaller than 100 µm seemed to be associated with more complications.https://www.mdpi.com/2075-4426/12/9/1530tendinopathyneovesselsembolizationimipenem/cilastatin |
| spellingShingle | Julien Ghelfi Ian Soulairol Olivier Stephanov Marylène Bacle Hélène de Forges Noelia Sanchez-Ballester Gilbert Ferretti Jean-Paul Beregi Julien Frandon Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents Journal of Personalized Medicine tendinopathy neovessels embolization imipenem/cilastatin |
| title | Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents |
| title_full | Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents |
| title_fullStr | Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents |
| title_full_unstemmed | Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents |
| title_short | Feasibility of Neovessel Embolization in a Large Animal Model of Tendinopathy: Safety and Efficacy of Various Embolization Agents |
| title_sort | feasibility of neovessel embolization in a large animal model of tendinopathy safety and efficacy of various embolization agents |
| topic | tendinopathy neovessels embolization imipenem/cilastatin |
| url | https://www.mdpi.com/2075-4426/12/9/1530 |
| work_keys_str_mv | AT julienghelfi feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT iansoulairol feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT olivierstephanov feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT marylenebacle feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT helenedeforges feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT noeliasanchezballester feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT gilbertferretti feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT jeanpaulberegi feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents AT julienfrandon feasibilityofneovesselembolizationinalargeanimalmodeloftendinopathysafetyandefficacyofvariousembolizationagents |